Kelonia Therapeutics

Kelonia Therapeutics is a biotech company focused on revolutionizing in vivo gene delivery, with a mission to expand the benefits and reach of genetic medicines. They are pioneering a new wave of genetic medicines using their in vivo gene placement system (iGPS®), a technology that utilizes an advanced lentiviral vector particle with envelope modifications to improve gene transfer efficiency and tissue-specific delivery. This technology allows for the development of transformational in vivo CAR T therapies for hematologic cancers, and Kelonia is building a pipeline of genetic medicines for a range of diseases.

Kelonia has a strong team of industry leaders in cell and gene therapy who are dedicated to making genetic medicines accessible to every patient in need, when and where they need them. They have secured significant Series A funding and established strategic collaborations with key industry partners like Adimab and ElevateBio to accelerate their mission. Kelonia's research has shown promising results in preclinical trials, highlighting the potential of their iGPS technology to bring safe, effective CAR T therapies to common medical practice for the treatment of all multiple myeloma patients.

Kelonia Therapeutics prioritizes work/life integration and offers a flexible work schedule and unlimited PTO. They also provide paid parental leave and generous company holidays. This flexible and generous benefits package demonstrates Kelonia's commitment to their employees' wellbeing.

Kelonia Therapeutics offers a comprehensive benefits package designed to prioritize its employees' well-being. This includes robust health insurance with low deductibles and employer-paid premiums, a flexible work schedule and unlimited PTO, paid parental leave, company holidays, and social gatherings. The company also provides additional benefits such as commuting assistance, life insurance, short and long-term disability, and an employee assistance program.

Kelonia Therapeutics is a biotechnology company dedicated to revolutionizing in vivo gene delivery and making genetic medicines accessible to every patient in need. Their mission is to democratize access to life-saving genetic therapies by developing a novel, efficient, and safe gene placement system (iGPS®) that enables precise and targeted delivery of therapeutic transgenes directly to the desired tissue within the patient's body. Kelonia's goal is to overcome the challenges of existing gene therapies, such as complexity, cost, and limited reach, to create "off-the-shelf" treatments that are both effective and widely available.

Kelonia Therapeutics promotes a human-first culture, prioritizing the well-being and development of its employees. This is reflected in their benefits package, which includes unlimited PTO, flexible work schedules, paid parental leave, and company-funded ancillary benefits like commuting and life insurance. They also emphasize work-life integration and community engagement through regular social gatherings and initiatives that give back to the local community.